CARGO Therapeutics — Investor Presentation (February 2025)
45 slides from CARGO Therapeutics's investor presentation, Feb 24, 2025
Slide 1: Corporate Presentation February 2025
Corporate Presentation February 2025 NASDAQ: CRGX Exhibit 99.1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. . In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “c
Slide 3: Near-term value-creating milestones in 2025 through 2027
N=18 dosed N=4+3m, N=5+6m N=8 dosed N=3+3m, N=1+6m Ph1 FPD Allo IND Allo FPD N=3 dosed N=6 dosed N=3+3m N=24 dosed N=3+3m, N=3+6m N=36 dosed N=18+3m, N=6+6m N=36 dosed N=12+3m, N=24+6m N=4 dosed 1 Enrollment assumptions are illustrative: plan to escalate only to DL2; mfg. capacity 3/mo. (dedicated s
Slide 4: Innovative pipeline for best-in-class potential in cell therapy
Innovative pipeline for best-in-class potential in cell therapy Stage of Development Autologous Program Target(s) Indication(s) Discovery IND-enabling Phase 1 Phase 2 Phase 3 Commercial rights CRG-023 (tri-specific, tri-cistronic CAR T) CD19 CD20 CD22 B-cell malignancies (LBCL, B-ALL)(1) Allogeneic
Slide 5: CRG-023 Overview
CRG-023 Overview Designed to deliver multiple, therapeutically beneficial transgene “cargo” from a single vector
Slide 6: Innovative tri-cistronic CAR T expresses three independent CARs from a single vector
Innovative tri-cistronic CAR T expresses three independent CARs from a single vector, each with its own costimulatory domain Three different co-stimulatory domains; Novel CD2 co-stim Designed to deliver multiple beneficial transgene “cargo” from a single vector CAR22 (m971-scFV)* 4-1BB CD3ζ CD28 CD
Slide 7: CAR-023 sustained anti-tumor function when activated by single antigen
CAR-023 sustained anti-tumor function when activated by single antigen Serial stim w/ Raji (CD19-, CD20-, CD22+) Serial stim w/ Raji (CD19+, CD20-, CD22-) Serial stim w/ Raji (CD19-, CD20+, CD22-) Tumor cells / well Days Control (NTD) CD22 CAR CAR-023 Days Tumor cells / well Control (NTD) CD19 CAR C
Slide 8: CAR-023 sustained anti-tumor activity in serial stimulation assays
CAR-023 sustained anti-tumor activity in serial stimulation assays Serial Stimulation Assay Day(s) n n n 0 Serial Stim with Raji Lymphoma (CD19+, CD20+, CD22+) Tumor cells / well Control (NTD) CD20 CAR CD22 CAR CD19 CAR CAR-023 Days n=3, mean±SEM Source: (CARGO ASH 2024 abstract, Barfi et al. 2024.
Slide 9: CAR-023 sustained long term tumor control relative to benchmarks
CAR-023 sustained long term tumor control relative to benchmarks Day 25 analysis: Serial Stim w/ Raji n=2, mean ± SEM Schematics of Benchmark Controls Utilized Failure Failing Benchmark CAR(s)-only comparison utilizes CARGO vector. Not a drug product comparison All Constructs but CRG-023 fail by Day
Slide 10: CRG-023 anti-lymphoma activity in vivo across antigen loss models
CRG-023 demonstrated impressive, anti-lymphoma activity in vivo across antigen loss models and at low doses + + Antigen Loss Lymphoma Model CRG-023 Low Dose Titration: Lymphoma Model Source: CARGO ASH 2024 abstract, Barfi et al. 2024. Raji CD19KO Raji CD20KO Raji CD22KO Raji 1:1:1
Slide 11: CRG-023 manufacturing process designed to evolve from autologous to allogeneic
CRG-023 manufacturing process designed to seamlessly evolve from autologous dose escalation to the allogeneic platform Process optimization guided by pre-clinical data while leveraging firi-cel execution experience Product characterization Dose escalation Considerations Process Reliability Preclinic
Slide 12: Good expansion characteristics across multiple healthy donors
Good expansion characteristics across multiple healthy donors Process confirmed using patient aph At-scale process demonstrated at CDMO Drug Product attributes including antigen specific potency assay demonstrated across range of batches CRG-023 process and analytical methods developed to produce dr
Slide 13: CRG-023 Summary
CRG-023 Summary Robust and comprehensive pre-clinical characterization establishing: Impressive, durable anti-tumor activity Low dose effectiveness in vivo Prevention of antigen escape Superior long term tumor control relative to competitive, clinically validated CARs Potential for best-in-class eff
Slide 14: Confidence in CRG-023 maintained with firi-cel learnings
Confidence in CRG-023 maintained with firi-cel learnings
Slide 15: CRG-023 targeting of CD22 offers a differentiated opportunity
CRG-023 targeting of CD22 offers a differentiated opportunity to achieve a best-in-class profile across B cell malignancies CRG-023 Total CAR CRG-023 vs Firi-cel CAR022 CAR expression levels heavily influence CAR T activity against a given antigen
Slide 16: Firi-cel CAR T expansion may associate with IEC-HS
Firi-cel CAR T expansion may associate with IEC-HS. CRG-023 vs firi-cel expansion potential are significantly differentiated preclinically CD22 CAR+ cells / uL Blood IEC-HS Grade Stanford Phase 1 CAR22 Study Hemophagocytic lymphohistiocytosis (HLH), is a severe hyper-inflammatory syndrome associated
Slide 17: Novel Allogeneic Platform
Novel Allogeneic Platform Universal vector with Best-in-Class engineering designed to limit rejection and enable conversion of autologous CAR T-cell therapy for broader patient benefit
Slide 18: Innovative, universal vector intended to enable allogeneic CAR T therapy
Innovative, universal vector intended to enable allogeneic CAR T therapy from any new or existing CAR CARGO’s differentiated approach: KD = Knockdown Allogeneic: Avoid immune rejection long enough to achieve durable response Autologous: T cell dysfunction limits efficacy Autologous: Scalability limi
Slide 19: Differentiated approach to limit allogeneic CAR T rejection
Differentiated approach to limit allogeneic CAR T rejection and achieve durable response Single vector to limit Host-vs-Graft rejection and prevent Graft-vs-Host disease
Slide 20: CARGO's allogeneic platform is a streamlined, universal approach
CARGO’s allogeneic platform is a streamlined, universal approach designed to solve the challenges of allogeneic cell therapy Company Approach Extending Persistence Immune Evasion / Cloaking Safety Preventing T cell toxicity Evading CD8+ T cells Evading CD4+ T cells Evading NK cells Mitigating GvHD G
Slide 21: Vectored transgene TCR suppression mitigates GvHD risk
Vectored transgene TCR suppression mitigates GvHD risk No Graft vs Host Disease symptoms observed in mouse model Orthogonal suppression to ablate TCR expression Key Features Gene X to prevent TCR export CD3 shRNA TBI (D-1) NSG Day 0 I.V. 30M Graft T Cells Day X Readouts: Body Weight GvHD Score Survi
Slide 22: Vectored transgene approach to limit NK cell-mediated rejection
Vectored transgene approach to limit NK cell-mediated rejection Cloaking approach to limit NK rejection Tuning MHC-I knockdown limits NK rejection Host NK TRAC KO NK Rejection Assay TRAC+B2M KO MHC Knockdown 1:1 E:T 3 donors
Slide 23: Three novel approaches to limit T cell-mediated rejection
Three, novel separate approaches to limit T cell-mediated rejection Approaches to limit CD4/CD8 T rejection Reduced host CD8+ T proliferation with CD8i Survival against primed alloreactive T cells Rejection Assay Host CD8 T TRAC KO TRAC+ B2M KO Primed Host T TRAC KO TRAC+ B2M KO Host CD8 T Prolifera
Slide 24: Preclinical proof-of-concept achieved across multiple CAR vectors
Preclinical proof-of-concept achieved across multiple CAR vectors *Early experimental POC, pre-TCR depletion * Planned Studies: CD19 CARs BCMA CARs GPC3 CARs Other targets These data for Allo CAR T utilized an aligned, research scale process
Slide 25: Comparable CAR anti-tumor activity demonstrated with allo vector
Comparable CAR anti-tumor activity demonstrated with allo vector CAR-023 Serial Killing Assay 1:6 E:T
Slide 26: Preliminary CMC PoC studies demonstrate impressive productivity
Preliminary CMC PoC studies demonstrate impressive productivity with desired drug product quality attributes Depletion At 1/8th manufacturing scale generate ≥1B therapeutic cells using bicistronic allo construct. Ultimate target is to scale to 3B seeding density to generate >10B therapeutics cells 9
Slide 27: Universal Allo Vector Summary
Universal Allo Vector Summary Lead candidate selection complete in Q1 2025 Established leading profile to prevent immune-based rejection with lead candidate vector(s) Demonstrated important feasibility of pairing an allogeneic vector with multiple, pre-existing CAR vectors and autologous process Ear
Slide 28: CRG-023 Develop Plan and Market Opportunity
CRG-023 Develop Plan and Market Opportunity
Slide 29: CRG-023 Phase 1 study design provides optionality for autologous and allogeneic modalities
CRG-023 Phase 1 study design provides optionality for both autologous and allogeneic modalities and across broad set of B-cell malignancies Includes both CAR Naïve and CAR experienced Additional indications opportunities: MCL, FL, autoimmune Dose escalation Dose expansion Evaluate safety, tolerabili
Slide 30: Significant market opportunity across B-cell malignancies
Significant market opportunity across B-cell malignancies with potentially best-in-class CAR T cell therapy LBCL 52,000 Treated LBCL patients in US 25,000 1L+ High Risk CLL MCL FL ALL (Adults) 18,000 2L+ CAR Naïve $450K CAR T price $450K CAR T price 4,500 CRG-023 treated patients 4,000 CRG-023 treat
Slide 31: CARGO leads with multiple shots on goal with best-in-class potential
CARGO leads with multiple shots on goal with best-in-class potential CRG-023 and possibility to leapfrog with allogeneic vectorized CRG-023 Key programs selected based on US clinical development. **In potentially pivotal studies. Auto Allo CARGO CRG-023** CD19 / CD20 / CD22 auto CAR T CRG-023 is cur
Slide 32: Allogeneic vectorized CRG-023 PoC could unlock value through partnerships
Allogeneic vectorized CRG-023 Proof-of-Concept (PoC) has the potential to unlock significant value through partnerships for CARGO and investors PoC enables multiplier effect through partnership Potential for multiple non-exclusive partnerships out-licensing CARGO allogeneic vector (indication agnost
Slide 33: Summary: Value creation possible by EOY'25 with milestones in 2026 and 2027
Summary: Value creation possible by EOY’25 with milestones in 2026 and 2027 with potential for significant upside Strong and seasoned management team with oncology and cell therapy expertise Portfolio of potentially best-in-class product (multicistronic construct of CRG-023) and platform (allogeneic
Slide 34: Thank you
Thank you
Slide 35: Pre-read Slides
Pre-read Slides CARGO THERAPEUTICS
Slide 36: Strong and seasoned leadership team with oncology and cell therapy experience
Recognized as strong and seasoned leadership team with significant oncology and cell therapy experience Gina Chapman President & Chief Executive Officer Anup Radhakrishnan Chief Operating Officer & Chief Financial Officer Michael Ports, PhD Chief Scientific Officer Shishir Gadam, PhD Chief Technical
Slide 37: CRG-023 a tri-specific CAR T designed to improve patient outcomes
Loss of co-stimulation Lack of T-cell persistence Antigen escape Expression of three specific chimeric antigen receptors Multi-specificity CAR-Engineered, CD2 technology New Co-Stim Technology New human binders, optimized CAR design, new MFG process multi-cistronic engineering Design & Engineering C
Slide 38: CRG-023 vector development approach enabled speed and reliable supply
HD runs Dose Escalation Expansion CRG-023 vector development approach enabled speed, functionality, portability of vector manufacturing and reliable supply Titer optimization by testing helper plasmid combinations Backbone pCCLc pCCLc pOXB pOXB pSup2KO pSup2KO Promoter MNDU3 MNDU3 MNDU3 MNDU3 MND MN
Slide 39: Confidence in CRG-023 maintained with firi-cel learnings
Confidence in CRG-023 maintained with firi-cel learnings Confidence in CRG-023 underscored by key differences in construct design and performance profile Targeting multiple antigens, including CD22, enables opportunity for best-in-class profile for CRG-023 ~80% of patients expressed CD22 (FIRCE-1),
Slide 40: FIRCE-1 Patient Characteristics Similar to Stanford Phase 1 Study
FIRCE-1 Patient Characteristics are Similar to Stanford Phase 1 Study Preliminary Data Baseline Cohort 1 (n=49) Stanford Dose level 1 (n=29) Age, years at screening median (min, max) >=65, n (%) 64.0 (19, 84) 29 (51%) 64 (25, 84) 14 (48%) Sex, male, n (%) 39(68%) 15 (52%) Race*, white, n (%) 34 (69%
Slide 41: Summary of FIRCE-1 data
Summary of FIRCE-1 data Response durability lower than Stanford Ph 1 results Cohort 1 N=51 Stanford DL1 N=29 ORR (CR+PR), n (%) 39 (77%) 19 (66%) CR 22 (43%) 15(52%) PR 17 (33%) SD 6 (12%) Preliminary Data CRG-022 treated patients with at least one post-baseline scan Cohort 1 N=45 Stanford DL1 N=29
Slide 42: MOA of CARGO's strategy to prevent GvHD and HvG
Under the hood: MOA of CARGO’s multifaceted strategy to prevent GvHD and HvG T cell Membrane MOA: Mechanism of Action, GVHD: Graft versus Host Disease, HvG: Host versus Graft
Slide 43: Thorough lead selection campaign for universal vector
Thorough lead selection campaign for universal vector ~600 all-in-one vectors ~1300 transgenes ~350 shRNAs Target Identification Engineer Transgenes Against Targets Protein and Vector Engineering Vector Assembly Identify targets that: Suppress TCR Limit immune rejection Build library of: Naturally o
Slide 44: Vector engineering and functional triage – path to lead selection v2.2
Vector engineering and functional triage – path to lead selection v2.2 NK Rejection T cell Rejection Host T cell Host NK CARGO’s ALLO v2.2 approach threads the needle between host T and NK cell rejection Version 2 vector candidates display superior performance across multiple assays than earlier ite
Slide 45: Allogeneic platform: potential to disrupt cell therapy manufacturing and supply chain
Cargo Allogeneic platform: Long-term potential to disrupt cell therapy manufacturing, supply chain and regulatory pathways Positive patient experience (TAT, slot management, supply chain) Single source of DP for multiple, indications, geographies Lower COGS Healthy donor cells-: Less variability in
CARGO Therapeutics — Investor Presentation (February 2025) on 6ix